Septerna (NASDAQ:SEPN) Posts Earnings Results, Beats Expectations By $0.14 EPS

Septerna (NASDAQ:SEPN) issued its quarterly earnings data on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14, FiscalAI reports. The business had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%.

Septerna Trading Up 0.1%

NASDAQ SEPN traded up $0.02 on Monday, hitting $38.85. 275,426 shares of the company were exchanged, compared to its average volume of 346,380. The company has a market cap of $1.75 billion, a PE ratio of -47.96 and a beta of 2.29. Septerna has a 12 month low of $10.62 and a 12 month high of $40.65. The stock has a fifty day moving average of $34.40 and a 200-day moving average of $29.02.

Insider Activity

In other news, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This represents a 13.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 47,828 shares of company stock worth $1,584,314 in the last quarter. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

Several hedge funds have recently bought and sold shares of the business. Group One Trading LLC lifted its stake in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the 4th quarter valued at about $35,000. Russell Investments Group Ltd. bought a new stake in Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna in the fourth quarter valued at approximately $53,000. Finally, Balyasny Asset Management L.P. bought a new stake in Septerna during the fourth quarter worth $100,000.

Wall Street Analysts Forecast Growth

SEPN has been the topic of several recent research reports. Raymond James Financial lifted their target price on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. Truist Financial raised their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Septerna in a research note on Wednesday, July 1st. Stifel Nicolaus began coverage on Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price on the stock. Finally, Guggenheim lowered their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.89.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.